MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN

• Published in: Biochemical and biophysical research communications Vol. 440; no. 4; pp. 604 - 610
• Main Authors: Li, Yan, Li, Li, Guan, Yan, Liu, Xiuju, Meng, Qingyong, Guo, Qisen
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2013
• Subjects: Apoptosis; carcinogenesis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; CDDP; Cell growth; Cell Proliferation; cisplatin; Cisplatin - therapeutic use; drug resistance; Drug Resistance, Neoplasm - genetics; gene expression regulation; Gene Expression Regulation, Neoplastic; Humans; in vitro studies; lung neoplasms; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; microRNA; MicroRNAs - genetics; MicroRNAs - physiology; MiR-92b; NSCLC; oncogenes; phenotype; PTEN; PTEN Phosphohydrolase - genetics; quantitative polymerase chain reaction; therapeutics; tissues; tumor suppressor genes; Up-Regulation; PTEN; Cell growth; CDDP; NSCLC; MiR-92b

•We found that miR-92b is significantly up-regulated in NSCLC tissues.•We demonstrated that miR-92b regulate A549 cell growth.•We claimed miR-92b regulates the resistance of NSCLC A549 cells to CDDP.•We suggested miR-92b directly target PTEN in NSCLC. MicroRNAs (miRNAs) have emerged to play importan...